SCHEMBL614300

SCHEMBL614300

COc1ccc(C)cc1C(CCN(C(C)C)C(C)C)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.68
CHRM1 P11229 3/20 0.68
HRH1 P35367 3/20 0.68
MAPT P10636 3/20 0.68
CHRM5 P08912 2/20 0.68
CHRM3 P20309 2/20 0.68
HTR2A P28223 2/20 0.68
LMNA P02545 1/20 0.68
ESR1 P03372 1/20 0.68
CHRM4 P08173 1/20 0.68
KCNE1 P15382 1/20 0.68
PTGS1 P23219 1/20 0.68
HRH2 P25021 1/20 0.68
SLC6A4 P31645 1/20 0.68
ADRA1A P35348 1/20 0.68
OPRK1 P41145 1/20 0.68
KCNQ1 P51787 1/20 0.68
KCNH2 Q12809 1/20 0.68
CACNA1C Q13936 1/20 0.68
SCN5A Q14524 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2522817 1.00 CHRM2 (0.68) CHRM2CHRM1HRH1MAPTCHRM5
Hydrochloric Acid SCHEMBL615546 0.99 CHRM2 (0.67) CHRM2CHRM1HRH1MAPTCHRM5
Bromide SCHEMBL2528600 0.99 CHRM2 (0.67) CHRM2CHRM1HRH1MAPTCHRM5
Bromide SCHEMBL2528597 0.99 CHRM2 (0.67) CHRM2CHRM1HRH1MAPTCHRM5
Fumaric Acid SCHEMBL1261697 0.91 CHRM2 (0.61) CHRM2CHRM1HRH1MAPTCHRM5
Fumaric Acid SCHEMBL1261695 0.91 CHRM2 (0.61) CHRM2CHRM1HRH1MAPTCHRM5
Cadaverine Tartrate SCHEMBL2528604 0.91 CHRM2 (0.74) CHRM2CHRM1HRH1MAPTCHRM5
Cadaverine Tartrate SCHEMBL2528602 0.91 CHRM2 (0.74) CHRM2CHRM1HRH1MAPTCHRM5
SCHEMBL9227827 0.91 MAPT (0.55) CHRM2CHRM1HRH1MAPTCHRM5
SCHEMBL9228278 0.90 CHRM2 (0.53) CHRM2CHRM1HRH1MAPTCHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041235-A1 PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF PHARMATHEN S.A. (GR) 2012-02-16 US claimed
US-8039672-B2 Method of obtaining 3,3-diphenylpropylamines INTERQUIM, S.A. (ES) 2011-10-18 US claimed
US-20100286446-A1 Method of Obtaining 3,3-Diphenylpropylamines INTERQUIM, S.A. (ES) 2010-11-11 US claimed
WO-2010092500-A2 A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE ALEMBIC LIMITED (IN) 2010-08-19 WO claimed
WO-2010046801-A2 A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE ALEMBIC LIMITED (IN) 2010-04-29 WO claimed
EP-1927585-A2 METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES Ragactives, S.L. (ES) 2008-06-04 EP claimed
EP-1698615-B1 METHOD OF OBTAINING TOLTERODINE RAGACTIVES SL (ES) 2007-10-31 EP claimed
EP-1419135-A4 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LAB LTD (IN) 2006-01-11 EP claimed
EP-1603862-A1 3,3-DIARYLPROPYLAMINE DERIVATIVES AND PROCESSES FOR ISOLATION THEREOF Ranbaxy Laboratories Limited (IN) 2005-12-14 EP claimed
US-20040249211-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES LIMITED (IN) 2004-12-09 US claimed
US-6822119-B1 REACTING 3,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-ONE WITH DIMETHYL SULFATE USING PHASE TRANSFER CATALYST; DESTERIFICATION, REDUCTION, AMINATION, SULFONATION, DEPROTECTING, DECYCLIZATION, AND SALT FORMATION RANBAXY LABORATORIES LIMITED (IN) 2004-11-23 US claimed
WO-2004078700-A1 3,3-DIARYLPROPYLAMINE DERIVATIVES AND PROCESSES FOR ISOLATION THEREOF RANBAXY LABORATORIES LIMITED (IN) 2004-09-16 WO claimed
EP-1419135-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES, LTD. (IN) 2004-05-19 EP claimed
WO-2003014060-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE RANBAXY LABORATORIES LIMITED (IN) 2003-02-20 WO claimed
EP-2007459-B1 INHALER BOEHRINGER INGELHEIM INT (DE) 2016-09-14 EP disclosed
EP-1927585-B1 METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES INTERQUIM SA (ES) 2016-07-27 EP disclosed
US-9085509-B2 Process for preparing fesoterodine ALEMBIC PHARMACEUTICALS LIMITED (IN) 2015-07-21 US disclosed
EP-0354234-A1 NEW AMINES, THEIR USE AND PREPARATION KabiVitrum AB (SE) 1990-02-14 EP disclosed
WO-1989006644-A1 NEW AMINES, THEIR USE AND PREPARATION KABIVITRUM AB (SE) 1989-07-27 WO disclosed
EP-0325571-A1 New amines, their use and preparation Kabi Pharmacia AB (SE) 1989-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249211-A1 PROCESS FOR THE PREPARATION OF TOLTERODINE ADRB3, ADRA1B, ADRA2B CHRM2 162/4885CHRM1 788/4885HRH1 1750/4885
US-20120041235-A1 PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF PAH, UGT1A7, MLN CHRM2 617/4885CHRM1 978/4885HRH1 3353/4885
US-20100286446-A1 Method of Obtaining 3,3-Diphenylpropylamines CHRM3, HRH4, ADRB3 CHRM2 4/4885CHRM1 29/4885HRH1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.